Filing Flows › Inhibrx Biosciences (INBX) › Recalls, complaints & regulation
Inhibrx Biosciences (INBX): clinical trials
Inhibrx Biosciences (INBX) beyond its filings: 4 active clinical trials.
Inhibrx Biosciences' latest quarter
Inhibrx Biosciences, Q2 2025: revenue $1.3M (13× year over year), net loss $28.7M, operating cash flow −$30.0M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Inhibrx Biosciences have?
4 active studies on ClinicalTrials.gov, 1 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.